We used the DHODH inhibitor brequinar, which has demonstrated promising effects in both human and murine AML models (26) and is currently under investigation in human clinical trials (ClinicalTrials.gov identifier: NCT03760666). This evidence concerns the gene DHODH and acute myeloid leukemia.